CalidiBiotherapeutics-Logo@2x.jpg
Calidi Biotherapeutics Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer
18 nov. 2024 08h00 HE | Calidi Biotherapeutics, Inc
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
CalidiBiotherapeutics-Logo@2x.jpg
Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock
15 nov. 2024 16h05 HE | Calidi Biotherapeutics, Inc
SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
CalidiBiotherapeutics-Logo@2x.jpg
Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock
14 nov. 2024 08h30 HE | Calidi Biotherapeutics, Inc
SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
CalidiBiotherapeutics-Logo@2x.jpg
Calidi Biotherapeutics Announces Proposed Public Offering
13 nov. 2024 16h33 HE | Calidi Biotherapeutics, Inc
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
CalidiBiotherapeutics-Logo@2x.jpg
Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results
12 nov. 2024 17h29 HE | Calidi Biotherapeutics, Inc
Announced FDA Clearance of the Northwestern University IND Application for NeuroNova (CLD-101) Clinical Trial in High-Grade Glioma.Presented data supporting RTNova (CLD-400), the company’s systemic...
CalidiBiotherapeutics-Logo@2x.jpg
Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences
24 oct. 2024 08h30 HE | Calidi Biotherapeutics, Inc
- RTNova, an innovative systemic antitumor enveloped virotherapy, unlocks new possibilities in cancer therapy - RTNova addresses challenges posed by untargetable and untreatable metastatic diseases,...
CalidiBiotherapeutics-Logo@2x.jpg
Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement
23 oct. 2024 08h31 HE | Calidi Biotherapeutics, Inc
SAN DIEGO, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
CalidiBiotherapeutics-Logo@2x.jpg
Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma
30 sept. 2024 08h00 HE | Calidi Biotherapeutics, Inc
Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma CLD-101 is Calidi’s novel allogeneic immunotherapy utilizing neural stem cells to deliver...
CalidiBiotherapeutics-Logo@2x.jpg
Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results
13 août 2024 17h37 HE | Calidi Biotherapeutics, Inc
Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi’s Adult Adipose Allogeneic (AAA) stem cell innovative programs Strengthened team with the appointment...
CalidiBiotherapeutics-Logo@2x.jpg
Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor
29 juil. 2024 09h00 HE | Calidi Biotherapeutics, Inc
SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...